TABLE 4.
Clinical outcomes
| Outcomes | 3 mo (n = 75) | 6 mo (n = 61) | 12 mo (n = 54) |
|---|---|---|---|
| Clinical success | 60 (80.0) | 48 (78.7) | 41 (76.0) |
| Absence of microbiological recurrence | 67 (89.3) | 55 (80.2) | 47 (87.0) |
| Clinician evaluated clinical improvement | 66 (88.0) | 56 (91.8) | 47 (87.0) |
| Omadacycline continuity (no switch for failure/AE) | 72 (96.0) | 58 (95.1) | 50 (92.6) |
| Survival | 75 (100.0) | 60 (98.4) | 52 (96.3) |
| Imaging improvement | (n = 30) | (n = 28) | (n = 22) |
| 18 (60.0) | 18 (64.3) | 15 (68.2) | |
| Culture conversion (≥2 consecutive negative cultures) (n = 52) | 43 (82.7) | ||
| Time to culture conversion, median (IQR), mo | 5 (2–11.5) | ||
a
Data reported as n (%), unless otherwise specified; OMC, omadacycline; AE, adverse event; IQR, interquartile range.